At the heart of IRE group

Our history
50 years of success

In 2021, IRE will celebrate its 50th anniversary. Half a century of innovations at the service of health and nuclear medicine.

1971 - 1973
  • Creation of IRE and first constructions.
1973 - 1978
  • First transfer of activities to Fleurus.
  • Construction of six buildings in record times.
  • First production runs of 131I and 99Mo.
  • Creation of a radioimmunology department.
  • Creation of a 60Co irradiation treatment unit.
  • Sterilization of medical equipment.
  • First production of 123I.
1978 - 1991
  • Creation of the production unit of 192Ir, for sealed sources.
  • Construction of the first cyclotron.
  • Pharmaceutical approval of the company.
  • Creation of molecules marked with tritium and 14C.
  • Production of tritiated thymidine.
  • Production of 85Kr fire detectors.
  • Production of 60Co discs.
  • Production of 192Ir industrial radiography equipment.
  • Development of injectable radioactive preparations based on 59Fe, 47Ca, 197Hg and 85Sr, as well as 192Ir sutures and pins (brachytherapy).
  • Creation of the concept for a repetitive elution 99mTc dry generator.
  • Creation of the transport subsidiary company TRANSRAD.
1991 - 2008
  • Impact of Regionalization on some of the IRE’s activities:
    • Sale of the radiopharmaceutical product lines to the NORDION group.
    • Divestment of the sterilization and radioimmunology testing activities.
    • Refocusing of the IRE activity on the core businesses with the production of the medical radioisotopes 99Mo, 131I and 133Xe.
  • Major investments in the context of the redeployment of radiopharmaceutical activities.
  • Development of equipment for the remote monitoring of environmental radioactivity and radiological monitoring missions within the territory.
  • Support by IRE of the development of the company IBA, which also invested in the Fleurus site (R&D activities supported by a prototype 14 MeV SE cyclotron).
2008 - 2010
  • Important expansion of international commercial activities. In addition to the European market, IRE takes a significant role as a major stakeholder in North America, Asia, and the Middle East. This achievement provided IRE with a leadership position in the production of 99Mo and 131I.
  • Substantial investments in the renovation of installations in terms of safety, security and quality.
  • Creation of the IRE ELiT subsidiary.
  • New development in radiopharmaceutical activities in the diagnostic and therapy sectors (90Y, 188Re, 68Ga, etc.).
  • Major consultancy contracts worldwide (European Commission, IAEA, etc.).
2010 - 2015
  • New IRE communication policy in relation to its environment.
  • Growth in revenue from 2010 to 2015: 140%.
  • Growth in headcount from 2010 to 2015: 53%.
  • Launch of research partnerships worldwide.
  • First partnership with Belgian universities in the field of medical research.
  • Major participation in the NEA/OECD High-Level Group (HLG) on the Security of Supply of Medical Radioisotopes.
  • Important IRE role in AIPES (Association of Imaging Producers & Equipment Suppliers).
  • Participation in the BioWin Health Cluster of the Walloon region (southern part of Belgium).
  • IRE ELiT launches Galli Eo (a Germanium-68/Gallium-68 generator) on the market, a major and totally innovative advance in the field of cancer imaging.
  • IRE announces a partnership with the company ASML, with the aim of developing a new method for the production of medical isotopes, without fission, such as Mo-99/Tc-99m. This is the beginning of the SMART project.
  • IRE and SCK CEN announce the signature of a Public-Public Partnership called RECUMO which provides a structural solution to manage the residues from the production of medical radioisotopes stored on the IRE site in Fleurus.

  • IRE ELiT takes a key step in the conquest of the radiopharmaceuticals market and obtains marketing authorisation in Europe for its Gallium-68 generator, which will henceforth be called Galli Ad on this territory.
  • The first transport of irradiated material was made from Fleurus to Mol. This transport is part of the public-public partnership between the IRE and SCK CEN.
  • IRE ELiT's Service Business Unit officially launched RAMSES, the first automatic real-time radiological monitoring system, on the market at the SFRP congress.
  • IRE officialises the acquisition of the activities of the Service Business Unit of its subsidiary IRE ELiT. The Business Unit Service is now called IRE Lab.

  • IRE ELiT and Isologic announce the approval of Gallium-68's generator, Galli Eo®, as a drug in Canada.
  • IRE and SCK CEN research centre sign a public-public partnership with the initial aim of producing the radioisotope lutetium-177 (Lu-177).

  • IRE ELiT extends its product range by launching a generator dedicated to pre-clinical research, Galli RD, on the world market.
1971 - 1973
1973 - 1978
1978 - 1991
1991 - 2008
2008 - 2010
2010 - 2015